Upstream Bio, Inc. (UPB) Stock Grade

About Upstream Bio, Inc.'s fundamentals

Upstream Bio is a biotech company with a $1.5 billion market capitalization that is growing revenue at a strong rate of 20.4% year-over-year. However, the company is currently unprofitable, operating at a net margin of -5026%, meaning it is burning significant cash relative to its revenue. The company does not pay dividends and reported a net loss in its latest annual statement, which is not uncommon for early-stage biotechnology firms still in development phases. Investors should evaluate the company's cash runway and progress toward commercializing its pipeline to assess long-term viability.